Ages2Come
Menu
View all results →
Categories
⚡ Breaking
Qualcomm stock pops 10% on data center infrastructure deal with Amazon Jim Cramer's top 10 things to watch in the stock market Tuesday Bitmine purchased another $69 million of ETH, with Tom DeMark expecting price uptrend to soon resume U.K. bans goods from occupied West Bank as Israel and U.S. warn of repercussions Whatever happened to the Taliban threat: 'We will flog the women'? Helping small businesses win with AI Poseidon Aerospace lands $60M ahead of first pilotless test flight How to right-click on a MacBook Property Play: Here’s where rental demand is heading and what it means for future home sales US regulator approves $1.9 billion loan to spin up Iowa's dead nuclear reactor for Google Qualcomm stock pops 10% on data center infrastructure deal with Amazon Jim Cramer's top 10 things to watch in the stock market Tuesday Bitmine purchased another $69 million of ETH, with Tom DeMark expecting price uptrend to soon resume U.K. bans goods from occupied West Bank as Israel and U.S. warn of repercussions Whatever happened to the Taliban threat: 'We will flog the women'? Helping small businesses win with AI Poseidon Aerospace lands $60M ahead of first pilotless test flight How to right-click on a MacBook Property Play: Here’s where rental demand is heading and what it means for future home sales US regulator approves $1.9 billion loan to spin up Iowa's dead nuclear reactor for Google
General

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

Source: cnbc September 8, 2026 · 05:03
Photo by Cnordic Nordic · Pexels
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Read original article ← Back to General

The original article opens on the publisher's website.

More from General

View topic →